145 results about "Total cholesterol" patented technology

The invention relates to the technical field of food, in particular to diglyceride for reducing triglyceride, cholesterol and uric acid as well as a biological enzyme preparation method and application of the diglyceride. The preparation method comprises the following steps: (1) adding water and glycerol into vegetable oil, and then adding immobilized lipase to react to obtain a reactant; (2) centrifuging reactants, collecting a light-phase product, carrying out molecular distillation, and collecting a heavy-phase product to obtain diglyceride; the immobilized lipase comprises lipase and a carrier, the carrier comprises loofah sponge, soybean meal and bentonite, and the mass ratio of the loofah sponge to the soybean meal to the bentonite is 1: (2-4): (3-6). The method has the advantages that the effects of reducing triglyceride, total cholesterol and uric acid are relatively good, and the yield and the purity are relatively high.

The invention discloses application of an overexpressed carp lpla gene in regulation and control of expression of cyprinid fish tissue-related genes, and relates to the field of gene engineering, in particular to application of the overexpressed carp lpla gene in regulation and control of cyprinid fish tissue-related genes. The overexpressed carp lpla gene is applied to regulation and control of contents of lipid indexes of total cholesterol TC and triglyceride TG of different tissues of cyprinid fishes. The invention further discloses application of the overexpressed carp lpla gene in regulation and control of fat marker genes lpla, ppar gamma, Fabp3, fast and acaca of livers and muscle tissues of cyprinid fishes. The invention further discloses application of the overexpressed carp lpla gene in regulating and controlling the relative expression quantity of carp liver cell fat metabolism related genes lpla, ppar gamma, Fabp3, fast, acaca, hsl and pnpla2. The overexpressed carp lpla gene can regulate and control lipid deposition in different tissues in zebra fish, and a research model is provided for lpla to regulate and control fat deposition and differentiation. According to the overexpressed carp lpla gene disclosed by the invention, lpla high-expression carp hepatocytes are obtained through a liposome transfection technology, so that fat key gene expression in the carp hepatocytes is changed.

The invention relates to a preparation method and application of a medicine-food homologous compound with weight-losing and lipid-lowering effects. According to the present invention, the weight of the obese mouse can be reduced by 23.23% at most, the serum total cholesterol is reduced, the leptin secretion is reduced, AST (aspartate transaminase) and ALT (alanine transaminase) have no significant difference compared to the model mouse, the volume of epididymal fat and inguinal fat cells is reduced, the number of cells in unit area is significantly increased, the fatty liver sample is relieved, the TMEM26 gene expression in the epididymal fat is significantly increased, and the weight of the obese mouse can be significantly reduced; the expression quantity of the UCP1 gene in brown fat is obviously increased. The traditional Chinese medicine composition adopts medicinal and edible substances as raw materials, is widely applicable to people, is more suitable for prevention and treatment of chronic diseases, is safe and effective, and causes little damage to liver and kidney after long-term use.

The invention relates to the technical field of intelligent health management, in particular to an intelligent nutrition intervention method based on underlying logic, which comprises the following steps: acquiring serum triglyceride, atherophilic lipoprotein cholesterol, anti-arterial lipoprotein cholesterol and total cholesterol concentration, collecting exhaled carbon dioxide release amount, and monitoring fatty acid oxidation rate. According to the method, through blood fat metabolism monitoring data, extraction of blood fat fluctuation characteristics, recognition of key abnormal time points, combination of fatty acid oxidation rate change, quantification of individual metabolic capability, adjustment of dietary fat composition, dietary fiber proportion and protein collocation, optimization of blood fat metabolism states and calculation of fat oxidation rate fluctuation, the fat oxidation rate fluctuation is calculated. According to the method, the influence of the feeding time on the blood fat change is evaluated, the optimal feeding time interval is matched, the dietary intake and the metabolic rhythm are coordinated, a personalized dietary adjustment scheme and the optimal feeding time are synthesized, the individual metabolic demand is matched, the pertinence and the adaptation degree of nutrition intervention are improved, and errors caused by intervention scheme generalization are avoided.

The invention discloses hippophae rhamnoides polysaccharide with the activity of reducing blood sugar and blood fat as well as a preparation method and application thereof. Adding water into the degreased hippophae rhamnoides, adjusting the pH value to be acidic, then heating, stirring and extracting under an ultrasonic condition, and collecting filtrate; and performing post-treatment to obtain the sea-buckthorn polysaccharide. The content of neutral sugar in the sea buckthorn polysaccharide is 25.31%-30.68%, the content of uronic acid in the sea buckthorn polysaccharide is 54.66%-59.79%, and the content of protein in the sea buckthorn polysaccharide is 1.91%-2.14%. According to the method, the sea-buckthorn polysaccharide is extracted by adopting acid assistance-ultrasonic extraction, and the prepared sea-buckthorn polysaccharide has remarkable blood sugar and blood fat reducing activity. When the concentration of the sea-buckthorn polysaccharide is as low as 0.1 mg / mL, the glucose uptake of HepG2-IR cells can still be obviously improved, and the content of total cholesterol and total triglyceride of the HepG2-IR cells can be obviously reduced. The hippophae rhamnoides polysaccharide can be applied to preparation of food or medicine for reducing blood sugar and / or blood fat.

The invention provides vinasse dietary fiber with blood fat reducing activity and a preparation method of the vinasse dietary fiber. The vinasse dietary fiber with relatively high purity is obtained by performing alkali soaking, sodium chlorite bleaching, crushing and drying on the vinasse. The prepared vinasse dietary fiber can effectively improve hyperlipidemia of obese diabetes model mice, reduce triglyceride and total cholesterol levels of serum and liver and improve liver injury, and can be applied to preparation of functional food, health care products, medicines and feeds with the blood glucose reducing effect.

The invention provides a lipid-lowering traditional Chinese medicine composition and extract as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The lipid-lowering traditional Chinese medicine composition is prepared from the following raw materials: rhizoma cyperi and radix gentianae. The invention further provides an extract of the lipid-lowering traditional Chinese medicine composition. The extract is obtained by mixing rhizoma cyperi and radix gentianae and then co-extracting. The composition or the extract can be used for preparing medicines for preventing and / or treating hyperlipemia, and can be used for improving lipid metabolism disorder of liver cells and reducing the content of triglyceride and total cholesterol in the liver cells.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a PPARalpha agonist combined with an NPC1L1 inhibitor in tumor treatment. Specifically, it is proved for the first time that systemic PKM2 deficiency can cause increase of the total cholesterol level and promote growth of homologous allograft tumors, and the phenomenon is partially attributed to increase of the expression level of intestinal NPC1L1. In addition, in breast cancer cells, PKM2 gene knockout not only weakens the activity of a PPARalpha signal channel, but also improves the expression of NPC1L1. Fenofibrate and Ezetimibe can be used for cooperatively inhibiting proliferation and metastasis of tumor cells in vitro and in vivo, so that the Fenofibrate and Ezetimibe have important clinical significance and social value.

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing visceral fat in a mammal is provided where the composition comprises an effective amount of Cissus quadrangularis provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

The application relates to the technical field of medicines, and discloses application of gymnemon and a medicine thereof.According to the application, the gymnemon can be used for preparing medicines related to cardiovascular diseases, including medicines for improving heart failure, inhibiting myocardial hypertrophy, improving vascular endothelial function and reducing blood pressure, and further used for preparing medicines for reducing expressions of vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 and / or increasing serum NO level; the gymnemon can also be used for preparing medicines for regulating abnormal lipid metabolism, including medicines for reducing triglyceride and total cholesterol level; the gymnemon can also be used for preparing medicines for relieving liver injury, including medicines for reducing glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase level; and the gymnemon can also be used for preparing medicines for improving systemic inflammation and / or platelet and thrombin dysfunction.

The invention discloses a functional solid beverage capable of reducing fat, losing weight and conditioning five highs. According to the functional solid beverage, dietary fibers such as fructo-oligosaccharide, inulin and the like are used for regulating intestinal flora, a white kidney bean extract is used for inhibiting the activity of alpha-amylase, L-carnitine is used for promoting fat transport, and medicinal and edible components such as ginseng, lotus leaves and the like are matched to realize multi-way metabolism regulation. The weight percentage of each component can be adjusted within a specified range so as to adapt to different physique requirements. Animal experiments prove that the total cholesterol (TC) of serum can be obviously reduced by 21.3-25.8% and the triglyceride (TG) can be obviously reduced by 28.9-34.2% after the traditional Chinese medicine is continuously taken for 4 weeks, and meanwhile, the insulin resistance index (HOMA-IR) can be improved to 16.5-20.3%.

The invention discloses application of lactobacillus fermentum E1 in preparation of fat-reducing and weight-losing products, and belongs to the technical field of microorganisms. The lactobacillus fermentum E1 disclosed by the invention can remarkably promote fat metabolism in the zebra fish body in vivo, can remarkably reduce the content of triglyceride and total cholesterol in the hyperlipidemia zebra fish body, and has the potential of being applied to losing weight and regulating the blood fat level; theoretical reference and guidance basis are provided for developing probiotic preparations for treating or preventing obesity and hyperlipidemia by using the lactobacillus fermentum E1.

The application provides a method, application and product for preparing a triglyceride oil with five effects of improving blood vessel health by enzymolysis, and belongs to the technical field of enzyme engineering. The preparation method comprises the following steps: mixing low erucic acid rapeseed oil, glycerol, water, fatty acid and lipase, performing enzymolysis reaction, performing molecular distillation, and performing decolorization and deodorization to obtain the triglyceride oil; the lipase is a mixture of Candida antarctica black Aspergillus niger lipase, Candida cylindracea lipase and bovine pancreas lipase; and the weight ratio of the low erucic acid rapeseed oil, glycerol, water, fatty acid and lipase is 500:80-100:1-2:30-60:10-20. The triglyceride oil prepared by the method can be used to prepare a triglyceride oil composition, and has the five effects of lowering blood uric acid, lowering blood total cholesterol, lowering blood triglyceride, lowering blood sugar and improving blood flow speed, thereby improving blood vessel health.

The invention provides application of golden amide alcohol ester or pharmaceutically acceptable salt thereof in preparation of medicines for preventing / treating fatty liver diseases and complications thereof. Compared with the prior art, the application has the following advantages: the application verifies that the auramide ester can obviously reduce the content of total cholesterol (TC) and triglyceride (TC) of a metabolism-related fatty liver disease model mouse, inhibit the activity of alanine transaminase (ALT), aspartate transaminase (AST) and low-density lipoprotein (LDL), inhibit the metabolism-related fatty liver disease model mouse, inhibit the metabolism-related fatty liver disease model mouse metabolism-related fatty liver disease mouse metabolism-related fatty liver disease mouse metabolism-related fatty liver disease mouse metabolism-related fatty liver disease mouse metabolism-related fatty liver disease mouse metabolism-related fatty liver disease mouse metabolism-related fatty liver disease mouse metabolism-related fatty liver disease mouse metabolism-related fatty Compared with the prior art, the invention has the advantages that the golden amide alcohol ester has obvious multiple effects of lowering lipid, resisting inflammation, resisting fibrosis and protecting liver, is basically non-toxic and good in safety, can be used for preparing the medicine for preventing / treating metabolism-related fatty liver diseases and related complications thereof, and has a wide application prospect.

The present application provides a polypeptide composition with anti-obesity effect, which is composed of capsaicin and polypeptides, and the amino acid sequence of the polypeptides comprises any one or more of SEQ ID NO. 1 to SEQ ID NO. 8. The polypeptides of sequences 1-8 are mixed uniformly at a mass ratio of 1-20:1-4:1-2:1-4:1:1:1:1, and the capsaicin is mixed with the mixed polypeptides at a ratio of 2-12:100 (w / w). The polypeptide composition proposed in the present application, in combination with capsaicin, not only promotes the weight loss effect of capsaicin, but also significantly reduces the fat index of the test mice after use, and can significantly reduce the total cholesterol concentration in the liver and the liver triglyceride concentration under a high-fat diet.

The invention discloses a compound polysaccharide preparation for treating diabetes and application thereof, and belongs to the technical field of biomedicine. The compound polysaccharide preparation is composed of compound polysaccharide A and compound polysaccharide B according to the mass ratio of 1: 1. The compound polysaccharide A is prepared from abelmoschus esculentus and chlorella through alkaline ultrasonic extraction and 10-100kDa ultrafiltration classification; the compound polysaccharide B is prepared by performing enzymolysis and hot water extraction on grifola frondosa and sarcodon aspratus. Experiments prove that the preparation can significantly improve insulin secretion and glucose uptake ability of islet cells, effectively reduce fasting blood-glucose of type 2 diabetes model mice and synchronously improve triglyceride and total cholesterol levels through strong synergistic interaction among the components. The preparation disclosed by the invention is natural in source, safe and efficient, so that a new choice is provided for medicine development of type 2 diabetes mellitus.

The invention discloses a lactobacillus paracasei LP007 probiotic liquid with a blood fat reducing effect and a preparation method of the lactobacillus paracasei LP007 probiotic liquid. On the basis of the casei paracasei LP007 and in combination with functional components such as the red yeast rice extract, the gamma-aminobutyric acid and the DHA, the probiotic liquid with the remarkable blood fat reducing effect is successfully prepared. Experiments show that the probiotic liquid can effectively reduce serum total cholesterol, low-density lipoprotein cholesterol and triglyceride, improve the level of high-density lipoprotein cholesterol and optimize lipid metabolism, and in addition, the formula can also improve intestinal flora balance, enhance the antioxidant capacity of the body, protect the liver to a certain extent, reduce fatty degeneration and improve the immunity of the human body. Compared with a contrast group without red yeast rice and GABA, the probiotic liquid has remarkable advantages in lipid-lowering effect, has good taste and biological stability, and is suitable for being drunk for a long time as a functional health product.

The present invention relates to the use of Akkermansia muciniphila in the preparation of a pharmaceutical composition for improving alcoholic liver dysfunction. The Akkermansia muciniphila is Akkermansia muciniphila AM06, Akkermansia muciniphila AM02, or a combination of the two; wherein the deposit number of AM06 is CGMCC No. 22793, and the deposit number of AM02 is CGMCC No. 22794. Improving alcoholic liver dysfunction includes preventing and treating alcoholic fatty liver. In this application, liver function indicators (such as ALT and AST) can be improved by reducing triglyceride levels and total cholesterol in the liver and serum, reducing liver fatty degeneration, etc., thereby effectively preventing the occurrence, development, and deterioration of alcoholic fatty liver. It also relates to the use of a composition containing the Akkermansia muciniphila in the preparation or use of a medicine for preventing and treating alcoholic fatty liver.

The invention discloses application of lactobacillus gasseri LS03 in preparation of fat-reducing and weight-losing products, and belongs to the technical field of microorganisms. The lactobacillus gasseri LS03 disclosed by the invention can remarkably promote fat metabolism in a zebra fish body in vivo, can remarkably reduce the content of triglyceride and total cholesterol in a hyperlipidemia zebra fish body, has the potential of being applied to losing weight and regulating the blood fat level, and can be used for preventing and treating hyperlipidemia. The lactobacillus gasseri LS03 provides theoretical reference and guidance basis for developing probiotic preparations for treating or preventing obesity and hyperlipidemia by utilizing the lactobacillus gasseri LS03.

The invention discloses an aquatic feed based on selenium yeast and application thereof, and belongs to the technical field of aquaculture. The invention relates to an aquatic feed additive based on selenium yeast, which systematically studies the influence of addition of different selenium sources (organic selenium and inorganic selenium) into feed on the growth performance, muscle nutrition, texture characteristics, serum biochemistry and main nutrient components of muscles of hybrid culter. The cultivation efficiency of the hybrid culter can be obviously optimized by enhancing the feed organic selenium, and the specific expression is as follows: the growth rate increase and the feed conversion efficiency improvement have obvious dose dependence; the selenium deposition amount and the crude protein enrichment degree in muscle tissue are synchronously improved, meanwhile, the synergistic effect of essential amino acid composition optimization (EAA / TAA value improvement) and n-3 series fatty acid characteristic enrichment is presented, and the two-way improvement of the nutritional quality and the flavor value is achieved from the molecular nutriology level. Mechanism research shows that the intervention strategy verifies the comprehensive regulation and control effect of the intervention strategy on the body health status by remarkably reducing the activity of serum transaminase (AST and ALT) and the total cholesterol concentration, effectively promoting the steady-state reconstruction of liver metabolism and activating an endogenous antioxidant defense system.

The invention discloses compound probiotics for reducing blood fat and regulating constipation and application of the compound probiotics in resistant starch fermented milk, and belongs to the technical field of functional food. The compound bacterium is prepared from bifidobacterium animalis IU100 and lactobacillus paracasei ZYhyy-004, and the compound bacterium has a synergistic interaction effect, and the compound bacterium can be used for preparing the compound bacterium. The resistant starch is used for preparing the resistant starch fermented milk, the levels of serum total cholesterol, triglyceride and low-density lipoprotein cholesterol can be remarkably reduced, the content of high-density lipoprotein cholesterol is increased, meanwhile, the intestinal tract propulsion rate is increased, and functional constipation is improved. The fermented milk realizes dual effects of reducing blood fat and improving intestinal functions by regulating intestinal flora balance, promoting proliferation of beneficial bacteria and inhibiting growth of pathogenic bacteria. The invention provides a new way for developing multifunctional probiotic foods.

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing fasting blood glucose in a mammal is provided where the composition comprises an effective amount of Dichrostachys glomerata provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

The invention relates to the field of intelligent medical treatment, in particular to a pregnancy disease risk prediction method and device based on biochemical indexes and a program product. Comprising the following steps: S1, acquiring serum biochemical index data of a pregnant woman; s2, comparing the serum biochemical indexes with a preset threshold value; the serum biochemical indexes include aspartate aminotransferase, total protein, albumin, lactic dehydrogenase, alkaline phosphatase, total bile acid, creatine kinase, blood sugar, urea nitrogen, uric acid, creatinine, glomerular filtration rate, potassium, chlorine, total calcium, serum magnesium, inorganic phosphorus, total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and homocysteine. When one or more of the myoglobin, the hypersensitive troponin I, the prealbumin, the cystatin C and the creatine kinase isoenzyme MB are abnormal, judging that the pregnancy eclampsia exists. The method is simple, convenient and rapid to operate and low in cost, can be clinically popularized to predict the health state of the pregnant woman on a large scale, and has good clinical value.

The present invention relates to a composition for alleviating obesity or improving lipid metabolism, comprising a Rostellularia procumbens extract. The Rostellularia procumbens extract according to the present invention has the effects of inhibiting weight gain and fat accumulation and lowering blood levels of total triglycerides, total cholesterol, and low-density lipoprotein. In addition, the Rostellularia procumbens extract of the present invention, as a natural medicinal agent, can be applied to various products such as pharmaceutical compositions, food compositions, and feed compositions for the prevention, treatment, or alleviation of obesity or for the improvement of lipid metabolism.

The main purpose of the present invention is to provide monascus and a composition for preventing or treating non-alcoholic fatty liver disease, the composition comprising the monascus and / or a monascus fermentation product thereof, or a functional component comprising the monascus fermentation product. The invention also aims to provide application of the monascus in preparation of the composition for preventing or treating the non-alcoholic fatty liver disease. The composition not only has the efficacy of reducing accumulation of total cholesterol (TC) and triglyceride (TG) in the non-alcoholic fatty liver disease caused by obesity, but also has the efficacy of reducing serum liver function indexes of asparaginic acid transaminase (AST) and alanine transaminase (ALT), so that the composition has the efficacy of preventing or treating the non-alcoholic fatty liver disease and related metabolic diseases thereof. , for example hyperlipidemia.

The application discloses a Hypsizygus marmoreus extract and a preparation method and application thereof. The extract is prepared from the Hypsizygus marmoreus through a method combining water extraction, alcohol precipitation, macroporous adsorption resin and silica gel column chromatography, UPLC-ESI-MS / MS analysis identifies 830 compounds, and 26 main compound components with a relative content of more than 0.2%; network pharmacology analysis obtains 40 active compounds and 23 T2MD related core target points. The extract can significantly reduce fasting blood glucose and postprandial blood glucose, can significantly reduce serum total cholesterol, triglyceride and low-density lipoprotein cholesterol levels, can improve fatty liver level, can significantly reduce serum inflammatory factors IL-6, TNF-alpha and CRP levels, can significantly increase GLP-1 and serum insulin levels, and can improve intestinal flora alpha diversity, improve beta diversity structure and restore the abundance of beneficial bacteria. The Hypsizygus marmoreus extract has multi-target and multi-metabolic regulation functions, can be used for developing a blood glucose and blood lipid reducing medicine or health food, and has high safety and definite effect.

The application relates to the field of biological medicine, and particularly relates to application of kaempferol-3-O-acacia di-saccharide-7-O-rhamnose glycoside in preparation of a medicine for preventing and / or treating diseases related to glycolipid metabolism disorder. The compound or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof can be used for treating diseases such as type 2 diabetes, insulin resistance, hyperglycemia, hyperlipidemia and non-alcoholic fatty liver disease. The compound can significantly reduce intracellular glucose, triglyceride and total cholesterol levels, and can play a role by activating an AKT signal pathway, so as to improve glycolipid metabolism disorder and has potential clinical application value.

The application belongs to the technical field of biological medicine, and particularly relates to application of a GCN2 kinase inhibitor in preparation of a drug for treating heart failure with preserved ejection fraction. 18 H 12 ClF2N5O3S, the inhibitor can inhibit the activity of GCN2 kinase, and exhibits significant therapeutic effect in a disease model: can obviously improve ventricular diastolic function (E / E' ratio is reduced), reduce the level of heart failure markers, reduce cardiomyocyte hypertrophy and interstitial fibrosis, inhibit the expression of oxidative stress level and inflammatory factors, reduce the accumulation of triglyceride and total cholesterol in myocardium and serum, and improve obesity-related insulin resistance and metabolic disorder. The application provides a novel targeted treatment strategy and candidate drug for heart failure with preserved ejection fraction.

The invention relates to application of aesculetin in preparation of a preparation for improving the health condition of poultry animals. The improved poultry animal abnormal indexes caused by heat stress comprise body weight, feed intake, daily gain, thymus index, spleen index, bursa of Fabricius index, thymus volume, spleen volume, bursa of Fabricius volume, total protein, serum albumin, interleukin-10, immune globulin A, immune globulin G, immune globulin M, triglyceride, total cholesterol and glutamic-pyruvic transaminase. The vaccine is prepared from the following raw materials: alkaline phosphatase, glutamic oxalacetic transaminase, urea nitrogen, lactic dehydrogenase, creatinine, heat shock protein 70, interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, interleukin-gamma, MyD88, TLR4, RELA, CD3 and CD19.

The invention discloses an application of a jerusalem artichoke tuber alcohol extract in preparation of a medicine for treating type 2 diabetes mellitus, and belongs to the technical field of medicines, the chemical components of the jerusalem artichoke tuber alcohol extract are mainly flavonoid substances, and the jerusalem artichoke tuber alcohol extract can remarkably recover the weight of a mouse with the type 2 diabetes mellitus and improve glucose metabolism indexes such as fasting blood-glucose and oral glucose tolerance; meanwhile, insulin sensitivity is stimulated to secrete insulin, and the functions of pancreatic beta cells are recovered; in addition, the concentration of biochemical indexes such as total cholesterol and triglyceride in the liver is reduced, lipid metabolism of the liver is improved, and a new direction is provided for research and development of natural plant source hypoglycemic products.